Mori N, Hidai H, Yokota J, Okada M, Motoji T, Oshimi K, Mizoguchi H
Department of Hematology, Tokyo Women's Medical College, Japan.
Leuk Res. 1995 Nov;19(11):869-75. doi: 10.1016/0145-2126(95)00058-5.
We analysed p53 mutations in 24 patients with myelodysplastic syndrome (MDS) and overt acute myeloid leukaemia after a period of MDS, using polymerase chain reaction-single strand conformation polymorphism analysis. In exons 5 to 8, mobility shifts were detected in five of the 24 patients. Sequence analysis was subsequently performed, and four missense mutations (16.7%) and one silent nucleotide substitution were identified. Patients harbouring mutations were characterized as having advanced disease. Loss of the wild type allele was observed in three of the four patients with missense mutations. No mobility shifts of the N-ras or FMS gene were detected in these four patients. We next analysed the correlation of the p53 mutations with the progression of MDS in three patients. The mutation was accompanied by the progression in two of the three patients. These findings suggest that mutations of the p53 gene are associated with progression in some cases of MDS, while being compatible with stable disease or clonal evolution in others.
我们运用聚合酶链反应-单链构象多态性分析方法,对24例骨髓增生异常综合征(MDS)患者以及经历一段MDS时期后转变为明显急性髓系白血病的患者的p53基因突变情况进行了分析。在第5至8外显子中,24例患者中有5例检测到迁移率改变。随后进行了序列分析,鉴定出4个错义突变(16.7%)和1个沉默核苷酸替代。携带突变的患者被特征化为患有晚期疾病。在4例错义突变患者中的3例观察到野生型等位基因缺失。在这4例患者中未检测到N-ras或FMS基因的迁移率改变。接下来,我们分析了3例患者中p53突变与MDS进展的相关性。在3例患者中的2例中,突变伴随着疾病进展。这些发现表明,p53基因的突变在某些MDS病例中与疾病进展相关,而在其他病例中则与疾病稳定或克隆进化相一致。